Efficacy and safety of modified BLd therapy for Japanese patients with transplant-ineligible multiple myeloma

Satsuki Murakami, Masaki Ri, Masato Ito, Nobuhiko Nakamura, Senji Kasahara, Junichi Kitagawa, Yuichiro Inagaki, Junya Kuroda, Makoto Yoshimitsu, Akinao Okamoto, Noriko Fukuhara, Hirofumi Taji, Hiroatsu Iida, Hirokazu Nagai, Ichiro Hanamura, Hideki Tsujimura, Miyuki Okura, Mio Kurata, Yachiyo Kuwatsuka, Yoshiko AtsutaShinsuke Iida

研究成果: Article査読


The BLd regimen, which is a triplet regimen of bortezomib (Bor), lenalidomide (Len), and dexamethasone (Dex), is effective against newly diagnosed multiple myeloma (NDMM). However, non-hematological toxicities, such as peripheral neuropathy (PN), often hamper long-term continuation of the regimen, particularly in older adult patients. In this study, we examined the efficacy and safety of the modified BLd regimen with reduced-intensity Bor and standard-dose Len. The chemotherapy regimen consisted of 1.3 mg/m2 Bor administered subcutaneously on days 1 and 8, 25 mg Len administered on days 1–14, and 20 mg Dex on days 1–2 and 8–9 of a 3 week cycle for 8 cycles, followed by a 4 week cycle of Dex (40 mg weekly). Among the 30 patients enrolled, 60.0% (95% CI 40.6–77.3) had a very good partial response or better, and the best overall response rate was 96.7% (95% CI 82.8–99.9). Eight patients (26.7%) achieved a complete response. Grade 3 or higher PN was not observed and hematological toxicity was the most common adverse event. The modified BLd regimen showed favorable efficacy with a manageable safety profile, which suggests it could be a treatment option for transplant-ineligible NDMM.

ジャーナルInternational Journal of Hematology
出版ステータスPublished - 10-2022

All Science Journal Classification (ASJC) codes

  • 血液学


「Efficacy and safety of modified BLd therapy for Japanese patients with transplant-ineligible multiple myeloma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。